Impfstoff BNT162b2 – 5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
Dokument: https://dudo.ch/uploads/2021/12/5.3.6-postmarketing-experience.pdf
Quelle: https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf